Pulsed Blood Plasma Dosing Regimen for Neurogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cognitive impairment, age-related dementia, motor impairment, and neurodegenerative diseases have limited success in preventing and reversing impairment, and there is a need for new treatments that optimize dosing paradigms to enhance neurogenesis and cognitive function.
Innovation Solution
The use of blood plasma or Plasma Fractions, derived from blood and blood plasma, administered through specific dosing regimens such as Pulsed Dosing, to stimulate neurogenesis, improve cognition, and reduce neuroinflammation, with the regimen optimizing cell survival and motor function, and maintaining efficacy even after the final dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for cognitive impairment and neurodegenerative diseases, then treatment is provided, but success in preventing and reversing impairment is limited
Solution Approach 1:
The patent changes the parameter of treatment composition from conventional therapies to blood plasma fractions, specifically optimizing the protein composition and concentration parameters to enhance neurogenesis and cognitive function while maintaining safety
2Reliability
If blood plasma is administered continuously, then neurogenesis and cognitive function are improved, but treatment complexity and duration increase
Solution Approach 1:
The patent implements periodic pulsed dosing regimens where blood plasma fractions are administered in discrete pulses rather than continuously, creating optimal intervals that maintain therapeutic effectiveness while reducing overall treatment complexity and duration
Solution Approach 2:
The patent applies preliminary action by administering blood plasma fractions before significant cognitive decline occurs, preventing the need for more complex and intensive later-stage interventions
3Productivity
If blood plasma fractions are used to stimulate neurogenesis, then cognitive function improves, but the duration of effect is limited by protein half-life
Solution Approach 1:
The patent achieves continuity of useful action through optimized pul dosing intervals that ensure blood plasma fraction proteins remain active and effective throughout their half-life, maintaining continuous neurogenic stimulation without unnecessary gaps or overlaps
Solution Approach 2:
The patent applies dynamics by adjusting dosing intervals and plasma fraction compositions based on the dynamic half-life characteristics of different proteins, optimizing the balance between stimulation duration and protein degradation rates
Data Source
AI summary
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.